Human Lymphocyte Bioassay for Anthrax Toxin Measurement

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for determining the efficacy of anti-anthrax therapeutics and diagnosing anthrax infections are limited by their reliance on animal models and species-specific in vitro assays that do not accurately reflect human cell responses to anthrax toxin, particularly in measuring anthrax lethal toxin (LT) activity.

Innovation Solution

Development of bioassays using human lymphocytes, such as CD4+ T-cells, to measure the proliferation and cytokine production in response to anthrax LT, allowing for the identification of therapeutic agents that decrease LT activity and diagnose anthrax infections by assessing MAPKK-dependent cytokine production.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If in vitro assays use mouse macrophage lines to measure anthrax LT activity, then the assay can detect toxin activity, but the results do not accurately reflect human cell responses

Engineering Contradiction:

Improveaccuracy of measuring anthrax LT activity in human cellsVSAvoidspecies-specific limitation of assay

Core Design Contradiction:

Measurement precisionVSAdaptability or versatility

Solution Approach 1:

The patent changes the cellular parameter from mouse macrophage lines to human lymphocyte cell lines (such as Jurkat cells), fundamentally altering the biological system being tested. This parameter change enables the assay to measure anthrax LT activity in a human cellular context, thereby improving measurement precision for human responses while eliminating species-specific limitations

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent develops human lymphocyte cell-based assays that can universally apply to human infection scenarios. By using human cell lines that respond to anthrax LT similarly to primary human cells, the assay achieves broad applicability across different human cell types and infection contexts, making it versatile rather than species-specific

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If in vivo efficacy testing is performed in animal models, then therapeutic efficacy can be assessed, but the results may not translate to human treatment outcomes

Engineering Contradiction:

Improvetherapeutic efficacy assessmentVSAvoidpredictive accuracy for human treatment

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent introduces human lymphocyte cell lines as an intermediary system between animal models and actual human patients. These cell lines serve as a human-relevant intermediate platform that can be tested in vitro, providing more reliable predictive data for human treatment outcomes while avoiding the limitations of animal models. The cell lines act as a mediator that bridges the gap between preclinical and clinical settings

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the mechanical/system-level animal model approach with a cellular-level in vitro assay system. By substituting whole-animal testing with human cell line assays, the methodology achieves more precise measurement of toxin effects on human cells while maintaining the ability to assess therapeutic efficacy in a controlled, translatable manner

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These bioassays provide a more accurate reflection of human cell responses to anthrax LT, enabling the identification of effective therapeutic agents and diagnosis of anthrax infections by measuring decreases in lymphocyte-associated LT activity and cytokine production.

Implementation Method 1

anthrax LT blocks production of MAPKK-dependent cytokines (such as IL-2, IL-4 and IFN-γ) and IL-2-dependent proliferation by primary human CD4+ T cells following T-cell receptor (TCR) stimulation

Methodology Applied

Scientific EffectMAPKK-dependent cytokine production inhibition:

Implementation Method 2

proliferation of lymphocytes and production of mitogen-activated protein kinase kinase (MAPKK)-dependent cytokines by stimulated T-cells, inversely correlate with anthrax lethal toxin (LT) levels in human cell assays

Methodology Applied

Scientific EffectLymphocyte proliferation:

Implementation Method 3

production of mitogen-activated protein kinase kinase (MAPKK)-dependent cytokines by stimulated T-cells

Methodology Applied

Scientific EffectCytokine production:

Data Source

PatentUS7803565B1Use of lymphocytes to measure anthrax lethal toxin activity

Publication Date: 2010.09.28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

AI summary

It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4+ T-cell can be used to determine an amount of lymphocyte-associated anthrax lethal toxin activity present. Methods of using isolated lymphocytes to identify anthrax therapeutic agents and to determine the efficacy of a potential anthrax therapeutic are disclosed. Methods are also provided for diagnosing and treating anthrax infections.